TY - CHAP M1 - Book, Section TI - Hepatitis C A1 - DeMaria, Jr., Alfred A2 - Boulton, Matthew L. A2 - Wallace, Robert B. PY - 2022 T2 - Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16e AB - Hepatitis C is a major public health challenge worldwide. It has evolved from a diagnosis of exclusion designated as “non-A, non-B hepatitis,”1 and principally associated with posttransfusion hepatitis, to an etiologically distinct disease; a major cause of cirrhosis, liver failure and hepatocellular carcinoma. The World Health Organization (WHO) estimates there are 71 million people infected with hepatitis C virus (HCV) worldwide, with 1,750,000 new infections in 2015 and about 400,000 deaths from the complications of infection.2 Others have estimated a much higher and increasing global prevalence, with 2.8% of the world’s population infected, translating to 185,000,000 infections, and substantially more disability and mortality than earlier estimates.3 The U.S. Centers for Disease Control and Prevention (CDC) notes that hepatitis C is now the leading cause of liver cancer and liver transplant in the United States, and that by 2013 the number of deaths associated with hepatitis C was greater than the mortality associated with 60 other nationally notifiable conditions combined.4 SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1182668430 ER -